Table 1 Baseline study population characteristics

Age, yrs

60 ± 10

64 ± 11

0.17

Male gender, n (%)

14 (100)

50 (96)

0.46

Previous MI, n (%)

13 (93)

46 (88,5)

0.63

Pre-ICD revascularization, n (%)

3 (21,4)

38 (73,1)

< 0.001

Previous PCI, n (%)

3 (21.4)

26 (50)

0.056

Previous CABG, n (%)

0 (0)

14 (26.9)

0.029

ICD indication, n (%)

Primary prevention

11 (78.6)

40 (76.9)

0.90

Secondary prevention

3 (21.4)

12 (23.1)

0.90

NYHA functionnal class

1.9 ± 0.7

2.0 ± 0.7

0.45

Hypertension, n (%)

3 (21.4)

25 (48.1)

0.07

Diabetes, n (%)

4 (28,6)

12 (23,1)

0.67

Device type, n (%)

ICD single chamber, n (%)

11 (78.6)

30 (57.7)

0.15

ICD dual chamber, n (%)

1 (7.1)

8 (15.4)

0.42

CRT-D, n (%)

2 (14.3)

14 (26.9)

0.33

ICD VT treatment zone lower setting (bpm)

168 ± 7

171 ± 8

0.24

ICD VF treatment zone lower setting (bpm)

216 ± 8

217 ± 7

0.66

Medication, n (%)

Beta-blocker

14 (100)

52 (100)

1.00

ACE inhibitor or ATII antagonist

14 (100)

50 (96.2)

0.46

Statin

13 (92.8)

49 (94.2)

0.85

Amiodarone

1 (7.1)

16 (30.8)

0.07

Diuretics

11 (78,7)

37 (71.1)

0.58

Aldosterone blockers

6 (42.9)

24 (46.1)

0.83

Aspirin or clopidogrel

14 (100)

51 (98.1)

0.60

QRS duration, ms

103 ± 24

117 ± 33

0.13

Left bundle branch block, n (%)

4 (28.6)

23 (44.2)

0.29

Right bundle branch block, n (%)

1 (7.1)

9 (17.3)

0.35

Follow-up, months

47 ± 18

41 ± 17

0.29